ViewRay : First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy Trial (MarketScreener)

ViewRay : First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy Trial

UF startup ViewRay, Inc. announces the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center clinical trial for locally advanced or borderline pancreatic cancer. The trial will explore the clinical benefits of high-dose radiation therapy enabled by MR-guidance, combined with daily on-table adaptation in the treatment of pancreatic cancer.

Retrospective analysis of high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at tracking quality of life over a five-year period in a controlled manner.

Learn more about Viewray : First Patient Enrolled in Stereotactic MRI-guided On-table Adaptive Radiation Therapy Trial.
X